4.6 Review

From Bench to Bedside: What Physicians Need to Know About Endothelial Progenitor Cells

Journal

AMERICAN JOURNAL OF MEDICINE
Volume 124, Issue 6, Pages 489-497

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjmed.2011.01.015

Keywords

Cardiovascular risk; Endothelial progenitor cells; Stem cells

Funding

  1. Austrian Society of Cardiology

Ask authors/readers for more resources

Since the discovery of endothelial progenitor cells in 1997, the scientific world has seen their ups and downs. There has been much discussion about the detection methods of endothelial progenitor cells and their diagnostic and predictive value. A lack of standardized methods to define endothelial progenitor cells has led to a number of nomenclatures and measuring methods that are difficult for clinicians to oversee. Therefore, only specialized hematologists and cardiologists were aware of their existence. Now it is time for a change: Most of the controversies have been eliminated by elaborate studies. This review aims to give an overview to the clinically working physician about the measurement, diagnostic potential, predictive value, and therapeutic potential of endothelial progenitor cells. (C) 2011 Elsevier Inc. All rights reserved. The American Journal of Medicine (2011) 124, 489-497

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available